Anatara Lifesciences Valuation

Is ANR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ANR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANR?

Key metric: As ANR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ANR. This is calculated by dividing ANR's market cap by their current book value.
What is ANR's PB Ratio?
PB Ratio8.2x
BookAU$1.36m
Market CapAU$11.19m

Price to Book Ratio vs Peers

How does ANR's PB Ratio compare to its peers?

The above table shows the PB ratio for ANR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.7x
CHM Chimeric Therapeutics
3.3xn/aAU$8.1m
NSB NeuroScientific Biopharmaceuticals
1xn/aAU$5.4m
TRP Tissue Repair
0.9xn/aAU$15.7m
PTX Prescient Therapeutics
1.7xn/aAU$31.4m
ANR Anatara Lifesciences
8.2xn/aAU$11.2m

Price-To-Book vs Peers: ANR is expensive based on its Price-To-Book Ratio (8.2x) compared to the peer average (1.7x).


Price to Book Ratio vs Industry

How does ANR's PB Ratio compare vs other companies in the AU Biotechs Industry?

1 CompanyPrice / BookEstimated GrowthMarket Cap
BNO Bionomics
0.3x-36.0%US$9.52m
No more companies available in this PB range
ANR 8.2xIndustry Avg. 3.1xNo. of Companies5PB0246810+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ANR is expensive based on its Price-To-Book Ratio (8.2x) compared to the Australian Biotechs industry average (3.1x).


Price to Book Ratio vs Fair Ratio

What is ANR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ANR's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies